Clinical pharmacology of angiotensin II receptor blockers: valsartan
https://doi.org/10.21518/2079-701X-2014-17-66-71
Abstract
Angiotensin II receptor blockers (ARBs), or sartans, are a group of pharmaceuticals that modulate the renin-angiotensin-aldosterone system (RAAS). They are more successful in blocking the effects of AT II compared to ACE inhibitors, and are characterized by higher tolerability. Large comparative studies with ARA II were completed lately, including studies on long-term efficacy and impact on prognosis. The obtained evidence base contributed to the expansion of indications for clinical use of sartans in the treatment of arterial hypertension (AH) and comorbid conditions. The action produced by ARBs is not age-dependent, not characterized by escape phenomenon in the context of long-term use; ARBs have implicit organ-protective and pleiotropic properties, and are metabolically neutral compared to other antihypertensive drugs. The available medications belonging to the ARB class have very specific pharmacological and pharmacokinetic properties that determine some of their clinical effects.
Keywords
антагонисты рецепторов АТ II,
сартаны,
фармакокинетика,
метаболизм,
гипотензивная эффективность,
органопротективные эффекты,
нефропротекция,
нейропротекция,
angiotensin II receptor blockers,
sartans,
pharmacokinetics,
metabolism,
antihypertensive effect,
organ-protective effects,
nephroprotection,
neuroprotection
About the Author
M. V. Leonova
Russian Medical Research University named after N.I. Pirogov, Moscow
Russian Federation
Russian Federation
References
1. Van Liefde I, Vauquelin G. Sartan-AT1 receptor interactions: in vitro evidence for insurmountable antagonism and inverse agonism. Molecular and Cellular Endocrinology, 2009, 302 (2): 237-57.
2. Zaman MA, Oparil S, Calhoun DA. Drugs targeting the renin-angiotensin-aldosterone system. Nat Rev Drug Discov, 2002, 1: 621-36.
3. Israili ZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension.J. Hum. Hypertens., 2000, 14(1): 73-86.
4. Miura S, Karnik SS, Saku K. Angiotensin II type 1 receptor blockers: class effects versus molecular effects. J Renin-Angiotensin-Aldosterone System., 2011, 12(1): 1-7.
5. Cabaleiro T, Roman M, Ochoa D et al. Evaluation of the Relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. DrugMetab Dispos, 2013, 41: 224-9.
6. Elmfeldt D, Olofsson B, Meredith P. The relationships between dose and antihypertensive effect of four ATj-receptor blockers. Differences in potency and efficacy. Blood Press, 2002, 11: 293-301.
7. Conlin PR. Angiotensin II Antagonists in the treatment of hypertension: more similarities than differences. J. Clin. Hypertens, 2000, 2: 253-7.
8. Nixon RM, Muller E, Lowy A, Falvey H. Valsartan vs. о^г angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach. Int. J. Clin. Pract, 2009, 63 (5): 766-75.
9. Abraham I, MacDonald K, Hermans C et al. Real-world effectiveness of valsartan on hypertension and total cardiovascular risk: review and implications of a translational research program. Vasc. Health Risk Manag, 2011, 7: 209-35.
10. Klingbeil AU, Schneider M, Martus P et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension.Am.J. Med, 2003, 115(1): 41-6.
Review
For citations:
Leonova MV. Clinical pharmacology of angiotensin II receptor blockers: valsartan. Meditsinskiy sovet = Medical Council. 2014;(17):66-71. (In Russ.) https://doi.org/10.21518/2079-701X-2014-17-66-71
Views:
1921
Email this article 